TNFSF10 and acute myeloid leukemia: Our findings reveal that TP53INP2 may serve as a potential biomarker for the selection of AML patients who respond better to TRAIL alone or in combination with VEN therapy, which provides a potentially individualized therapeutic strategy for TP53INP2-positive AML patients.